Abstract
Bipolar I disorder is a chronic disorder characterized by episodic recurrences of mania, depression, and mixed affective states interspersed with periods of full or partial remission; subsyndromal residual symptoms between episodes are common and disabling. Cariprazine, an atypical antipsychotic, is a potent dopamine D3 and D2 receptor partial agonist with preferential binding to D3 receptors. Post-hoc analyses of pooled data from 3 positive trials were conducted to evaluate the effect of cariprazine 3-12mg/d on the symptoms of mania in inpatients (18-65 years) with bipolar I disorder and a current manic episode. Analyses were based on the pooled intent-to-treat (ITT) population (placebo=429; cariprazine=608). Mean change from baseline to the end of treatment on individual Young Mania Rating Scale (YMRS) items was analysed using a mixed-effects model for repeated measures (MMRM); categorical symptom severity shifts were analysed using logistic regression. Statistically significant improvement in mean change was seen for cariprazine versus placebo on all 11 YMRS items (p
Original language | English (US) |
---|---|
Pages (from-to) | 1882-1891 |
Number of pages | 10 |
Journal | European Neuropsychopharmacology |
Volume | 25 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2015 |
Externally published | Yes |
Keywords
- Atypical antipsychotic
- Bipolar disorder
- Bipolar mania
- Cariprazine
- Residual symptoms
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Pharmacology (medical)
- Biological Psychiatry
- Neurology
- Pharmacology